ID   1433G_HUMAN             Reviewed;         247 AA.
AC   P61981; O70457; P35214; Q6FH52; Q9UDP2; Q9UN99;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   05-DEC-2018, entry version 163.
DE   RecName: Full=14-3-3 protein gamma;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein gamma, N-terminally processed;
GN   Name=YWHAG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION, AND INTERACTION WITH
RP   RAF1.
RC   TISSUE=Vascular smooth muscle;
RX   PubMed=10433554; DOI=10.1089/104454999315105;
RA   Autieri M.V., Carbone C.J.;
RT   "14-3-3gamma interacts with and is phosphorylated by multiple protein
RT   kinase C isoforms in PDGF-stimulated human vascular smooth muscle
RT   cells.";
RL   DNA Cell Biol. 18:555-564(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10486217; DOI=10.1006/geno.1999.5887;
RA   Horie M., Suzuki M., Takahashi E., Tanigami A.;
RT   "Cloning, expression, and chromosomal mapping of the human 14-3-3gamma
RT   gene (YWHAG) to 7q11.23.";
RL   Genomics 60:241-243(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrial tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-10; 29-50; 62-77; 133-198 AND 228-247,
RP   INTERACTION WITH PI4KB; TBC1D22A AND TBC1D22B, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=23572552; DOI=10.1128/mBio.00098-13;
RA   Greninger A.L., Knudsen G.M., Betegon M., Burlingame A.L.,
RA   DeRisi J.L.;
RT   "ACBD3 interaction with TBC1 domain 22 protein is differentially
RT   affected by enteroviral and kobuviral 3A protein binding.";
RL   MBio 4:E00098-E00098(2013).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-10; 13-56; 62-69; 133-172 AND 199-227, CLEAVAGE
RP   OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND VAL-2,
RP   PHOSPHORYLATION AT THR-145, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [8]
RP   PROTEIN SEQUENCE OF 2-12.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-10; 13-19; 29-42; 62-69; 133-143 AND 218-227,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 92-110; 199-217 AND 228-247, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [12]
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14534293; DOI=10.1074/jbc.M309039200;
RA   Towbin H., Bair K.W., DeCaprio J.A., Eck M.J., Kim S., Kinder F.R.,
RA   Morollo A., Mueller D.R., Schindler P., Song H.K., van Oostrum J.,
RA   Versace R.W., Voshol H., Wood J., Zabludoff S., Phillips P.E.;
RT   "Proteomics-based target identification: bengamides as a new class of
RT   methionine aminopeptidase inhibitors.";
RL   J. Biol. Chem. 278:52964-52971(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A.,
RA   Mann M.;
RT   "Proteomic characterization of the human centrosome by protein
RT   correlation profiling.";
RL   Nature 426:570-574(2003).
RN   [14]
RP   INTERACTION WITH CRTC2.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [15]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [16]
RP   INTERACTION WITH ABL1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [17]
RP   FUNCTION IN TP53 ACTIVATION, AND INTERACTION WITH MDM4.
RX   PubMed=16511572; DOI=10.1038/sj.emboj.7601010;
RA   Jin Y., Dai M.S., Lu S.Z., Xu Y., Luo Z., Zhao Y., Lu H.;
RT   "14-3-3gamma binds to MDMX that is phosphorylated by UV-activated
RT   Chk1, resulting in p53 activation.";
RL   EMBO J. 25:1207-1218(2006).
RN   [18]
RP   INTERACTION WITH SIRT2.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the
RT   activity of p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [19]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT VAL-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   INTERACTION WITH SLITRK1.
RX   PubMed=19640509; DOI=10.1016/j.biopsych.2009.05.033;
RA   Kajiwara Y., Buxbaum J.D., Grice D.E.;
RT   "SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a
RT   phosphorylation-dependent manner.";
RL   Biol. Psychiatry 66:918-925(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-234 AND SER-235, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   INTERACTION WITH DAPK2.
RX   PubMed=26047703; DOI=10.1016/j.bbrc.2015.05.105;
RA   Yuasa K., Ota R., Matsuda S., Isshiki K., Inoue M., Tsuji A.;
RT   "Suppression of death-associated protein kinase 2 by interaction with
RT   14-3-3 proteins.";
RL   Biochem. Biophys. Res. Commun. 464:70-75(2015).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [29]
RP   INVOLVEMENT IN EIEE56, VARIANTS EIEE56 ALA-15; GLU-129 AND CYS-132,
RP   AND VARIANTS GLN-50 AND SER-133.
RX   PubMed=28777935; DOI=10.1016/j.ajhg.2017.07.004;
RG   Epilepsy Genomics Study;
RG   Deciphering Developmental Disorders Study;
RA   Guella I., McKenzie M.B., Evans D.M., Buerki S.E., Toyota E.B.,
RA   Van Allen M.I., Suri M., Elmslie F., Simon M.E.H., van Gassen K.L.I.,
RA   Heron D., Keren B., Nava C., Connolly M.B., Demos M., Farrer M.J.;
RT   "De novo mutations in YWHAG cause early-onset epilepsy.";
RL   Am. J. Hum. Genet. 101:300-310(2017).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS), IDENTIFICATION BY MASS
RP   SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC       {ECO:0000269|PubMed:16511572}.
CC   -!- SUBUNIT: Homodimer. Interacts with SAMSN1 (By similarity).
CC       Interacts with RAF1, SSH1 and CRTC2/TORC2. Interacts with ABL1
CC       (phosphorylated form); the interaction retains it in the
CC       cytoplasm. Interacts with GAB2. Interacts with MDM4
CC       (phosphorylated); negatively regulates MDM4 activity toward TP53.
CC       Interacts with PKA-phosphorylated AANAT and SIRT2.Interacts with
CC       the 'Thr-369' phosphorylated form of DAPK2 (PubMed:26047703).
CC       Interacts with PI4KB, TBC1D22A and TBC1D22B (PubMed:23572552).
CC       Interacts with SLITRK1 (PubMed:19640509). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P61982, ECO:0000269|PubMed:10433554,
CC       ECO:0000269|PubMed:11427721, ECO:0000269|PubMed:15159416,
CC       ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:15696159,
CC       ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:17085597,
CC       ECO:0000269|PubMed:18249187, ECO:0000269|PubMed:19172738,
CC       ECO:0000269|PubMed:19640509, ECO:0000269|PubMed:23572552,
CC       ECO:0000269|PubMed:26047703}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-359832, EBI-359832;
CC       Q9HC77:CENPJ; NbExp=3; IntAct=EBI-359832, EBI-946194;
CC       O14757:CHEK1; NbExp=7; IntAct=EBI-359832, EBI-974488;
CC       P67828:CSNK1A1 (xeno); NbExp=3; IntAct=EBI-359832, EBI-7540603;
CC       Q9NYF3:FAM53C; NbExp=4; IntAct=EBI-359832, EBI-1644252;
CC       P56524:HDAC4; NbExp=7; IntAct=EBI-359832, EBI-308629;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-359832, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=4; IntAct=EBI-359832, EBI-5323863;
CC       Q7KZI7:MARK2; NbExp=2; IntAct=EBI-359832, EBI-516560;
CC       P27448:MARK3; NbExp=2; IntAct=EBI-359832, EBI-707595;
CC       O15151:MDM4; NbExp=7; IntAct=EBI-359832, EBI-398437;
CC       P26045:PTPN3; NbExp=3; IntAct=EBI-359832, EBI-1047946;
CC       P61588:Rnd3 (xeno); NbExp=2; IntAct=EBI-359832, EBI-6930266;
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-359832, EBI-717399;
CC       P04637:TP53; NbExp=5; IntAct=EBI-359832, EBI-366083;
CC       P31946:YWHAB; NbExp=2; IntAct=EBI-359832, EBI-359815;
CC       P62258:YWHAE; NbExp=5; IntAct=EBI-359832, EBI-356498;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, skeletal muscle,
CC       and heart. {ECO:0000269|PubMed:10486217}.
CC   -!- PTM: Phosphorylated by various PKC isozymes.
CC       {ECO:0000269|PubMed:10433554, ECO:0000269|Ref.7}.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 56 (EIEE56)
CC       [MIM:617665]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent. EIEE56 is an
CC       autosomal dominant condition. {ECO:0000269|PubMed:28777935}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family. {ECO:0000305}.
DR   EMBL; AF142498; AAD48408.1; -; mRNA.
DR   EMBL; AB024334; BAA85184.1; -; mRNA.
DR   EMBL; CR541904; CAG46702.1; -; mRNA.
DR   EMBL; CR541925; CAG46723.1; -; mRNA.
DR   EMBL; AC006388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020963; AAH20963.1; -; mRNA.
DR   CCDS; CCDS5584.1; -.
DR   RefSeq; NP_036611.2; NM_012479.3.
DR   PDB; 2B05; X-ray; 2.55 A; A/B/C/D/E/F=2-247.
DR   PDB; 3UZD; X-ray; 1.86 A; A=1-247.
DR   PDB; 4E2E; X-ray; 2.25 A; A=1-247.
DR   PDB; 4J6S; X-ray; 3.08 A; A/B/C/D=1-247.
DR   PDB; 4O46; X-ray; 2.90 A; A/B/C/D/E/F=1-247.
DR   PDB; 5D3E; X-ray; 2.75 A; A/B/E/F/I/J=1-238.
DR   PDB; 6BYJ; X-ray; 2.90 A; A/B/C/D/E/F=2-241.
DR   PDB; 6BYL; X-ray; 3.35 A; A/B/C/D/E/F=2-241.
DR   PDB; 6BZD; X-ray; 2.67 A; A/B/C/D=2-247.
DR   PDB; 6FEL; X-ray; 2.84 A; A/B/C/D=1-234.
DR   PDB; 6GKF; X-ray; 2.60 A; A/B/C/D/E/F/G/H=1-234.
DR   PDB; 6GKG; X-ray; 2.85 A; A/B/C/D/E/F/G/H=1-234.
DR   PDBsum; 2B05; -.
DR   PDBsum; 3UZD; -.
DR   PDBsum; 4E2E; -.
DR   PDBsum; 4J6S; -.
DR   PDBsum; 4O46; -.
DR   PDBsum; 5D3E; -.
DR   PDBsum; 6BYJ; -.
DR   PDBsum; 6BYL; -.
DR   PDBsum; 6BZD; -.
DR   PDBsum; 6FEL; -.
DR   PDBsum; 6GKF; -.
DR   PDBsum; 6GKG; -.
DR   ProteinModelPortal; P61981; -.
DR   SMR; P61981; -.
DR   BioGrid; 113364; 331.
DR   CORUM; P61981; -.
DR   DIP; DIP-33406N; -.
DR   ELM; P61981; -.
DR   IntAct; P61981; 135.
DR   MINT; P61981; -.
DR   STRING; 9606.ENSP00000306330; -.
DR   BindingDB; P61981; -.
DR   ChEMBL; CHEMBL1293296; -.
DR   iPTMnet; P61981; -.
DR   PhosphoSitePlus; P61981; -.
DR   SwissPalm; P61981; -.
DR   BioMuta; YWHAG; -.
DR   DMDM; 48428721; -.
DR   REPRODUCTION-2DPAGE; IPI00220642; -.
DR   EPD; P61981; -.
DR   MaxQB; P61981; -.
DR   PaxDb; P61981; -.
DR   PeptideAtlas; P61981; -.
DR   PRIDE; P61981; -.
DR   TopDownProteomics; P61981; -.
DR   DNASU; 7532; -.
DR   Ensembl; ENST00000307630; ENSP00000306330; ENSG00000170027.
DR   GeneID; 7532; -.
DR   KEGG; hsa:7532; -.
DR   UCSC; uc011kgj.2; human.
DR   CTD; 7532; -.
DR   DisGeNET; 7532; -.
DR   EuPathDB; HostDB:ENSG00000170027.6; -.
DR   GeneCards; YWHAG; -.
DR   HGNC; HGNC:12852; YWHAG.
DR   HPA; CAB013274; -.
DR   HPA; CAB018389; -.
DR   HPA; HPA026918; -.
DR   MalaCards; YWHAG; -.
DR   MIM; 605356; gene.
DR   MIM; 617665; phenotype.
DR   neXtProt; NX_P61981; -.
DR   OpenTargets; ENSG00000170027; -.
DR   Orphanet; 442835; Undetermined early-onset epileptic encephalopathy.
DR   PharmGKB; PA37441; -.
DR   eggNOG; KOG0841; Eukaryota.
DR   eggNOG; COG5040; LUCA.
DR   GeneTree; ENSGT00940000153764; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P61981; -.
DR   KO; K16198; -.
DR   OMA; NELSKIC; -.
DR   OrthoDB; EOG091G0VKY; -.
DR   PhylomeDB; P61981; -.
DR   TreeFam; TF102003; -.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; P61981; -.
DR   SIGNOR; P61981; -.
DR   ChiTaRS; YWHAG; human.
DR   EvolutionaryTrace; P61981; -.
DR   GeneWiki; YWHAG; -.
DR   GenomeRNAi; 7532; -.
DR   PRO; PR:P61981; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000170027; Expressed in 210 organ(s), highest expression level in lateral nuclear group of thalamus.
DR   CleanEx; HS_YWHAG; -.
DR   Genevisible; P61981; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0098793; C:presynapse; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0008426; F:protein kinase C inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0097711; P:ciliary basal body-plasma membrane docking; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; NAS:UniProtKB.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; NAS:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IMP:UniProtKB.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR036815; 14-3-3_dom_sf.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Epilepsy; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN         1    247       14-3-3 protein gamma.
FT                                /FTId=PRO_0000367907.
FT   INIT_MET      1      1       Removed; alternate.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:14534293,
FT                                ECO:0000269|Ref.7, ECO:0000269|Ref.9}.
FT   CHAIN         2    247       14-3-3 protein gamma, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000058606.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        132    132       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                gamma; alternate; partial.
FT                                {ECO:0000269|Ref.7}.
FT   MOD_RES       2      2       N-acetylvaline; in 14-3-3 protein gamma,
FT                                N-terminally processed; partial.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|PubMed:14534293,
FT                                ECO:0000269|Ref.7, ECO:0000269|Ref.9}.
FT   MOD_RES       2      2       N-acetylvaline; partial.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|PubMed:14534293,
FT                                ECO:0000269|Ref.7, ECO:0000269|Ref.9}.
FT   MOD_RES      71     71       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     133    133       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P61983}.
FT   MOD_RES     145    145       Phosphothreonine. {ECO:0000269|Ref.7}.
FT   MOD_RES     215    215       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P61983}.
FT   MOD_RES     234    234       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     235    235       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT      15     15       E -> A (in EIEE56; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28777935}.
FT                                /FTId=VAR_080224.
FT   VARIANT      50     50       K -> Q (found in an individual with
FT                                autism; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28777935}.
FT                                /FTId=VAR_080225.
FT   VARIANT     129    129       D -> E (in EIEE56).
FT                                {ECO:0000269|PubMed:28777935}.
FT                                /FTId=VAR_080226.
FT   VARIANT     132    132       R -> C (in EIEE56).
FT                                {ECO:0000269|PubMed:28777935}.
FT                                /FTId=VAR_080227.
FT   VARIANT     133    133       Y -> S (probable disease-associated
FT                                mutation found in an individual with
FT                                neurodevelopmental disorder).
FT                                {ECO:0000269|PubMed:28777935}.
FT                                /FTId=VAR_080228.
FT   CONFLICT      4      4       R -> P (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT     19     19       R -> G (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       Missing (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT     89     89       I -> V (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    104    104       L -> V (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       I -> Y (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    119    122       SKVF -> RKDL (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    144    145       AT -> GD (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    157    158       AH -> R (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    200    202       AFD -> EFE (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    214    214       D -> E (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   CONFLICT    240    240       D -> DH (in Ref. 1; AAD48408).
FT                                {ECO:0000305}.
FT   HELIX         4     16       {ECO:0000244|PDB:3UZD}.
FT   HELIX        20     31       {ECO:0000244|PDB:3UZD}.
FT   TURN         32     34       {ECO:0000244|PDB:6FEL}.
FT   HELIX        39     70       {ECO:0000244|PDB:3UZD}.
FT   TURN         71     73       {ECO:0000244|PDB:6BYJ}.
FT   TURN         76     78       {ECO:0000244|PDB:6FEL}.
FT   HELIX        79    106       {ECO:0000244|PDB:3UZD}.
FT   HELIX       108    111       {ECO:0000244|PDB:3UZD}.
FT   HELIX       117    137       {ECO:0000244|PDB:3UZD}.
FT   HELIX       140    164       {ECO:0000244|PDB:3UZD}.
FT   HELIX       170    185       {ECO:0000244|PDB:3UZD}.
FT   HELIX       190    206       {ECO:0000244|PDB:3UZD}.
FT   HELIX       207    210       {ECO:0000244|PDB:3UZD}.
FT   TURN        213    215       {ECO:0000244|PDB:3UZD}.
FT   HELIX       216    233       {ECO:0000244|PDB:3UZD}.
FT   HELIX       237    240       {ECO:0000244|PDB:6BYL}.
SQ   SEQUENCE   247 AA;  28303 MW;  B0D16C6DE1F4455D CRC64;
     MVDREQLVQK ARLAEQAERY DDMAAAMKNV TELNEPLSNE ERNLLSVAYK NVVGARRSSW
     RVISSIEQKT SADGNEKKIE MVRAYREKIE KELEAVCQDV LSLLDNYLIK NCSETQYESK
     VFYLKMKGDY YRYLAEVATG EKRATVVESS EKAYSEAHEI SKEHMQPTHP IRLGLALNYS
     VFYYEIQNAP EQACHLAKTA FDDAIAELDT LNEDSYKDST LIMQLLRDNL TLWTSDQQDD
     DGGEGNN
//